Literature DB >> 16470011

Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process.

Charles A Dinarello1.   

Abstract

In this review, 2 cytokines are discussed with respect to the inflammatory processes that are fundamental to aging and mortality. Both interleukin (IL)-1 and IL-18 are members of the same structural family (IL-1 family, or IL-F); there are presently 9 members of this family, but with the exception of IL-1alpha, IL-1beta, and IL-18, the others are antagonists or remain without known function. IL-1alpha is an intracellular cytokine with properties of both a cytokine and a transcription factor. IL-1beta and IL-18 are closely related; both possess a similar three-dimensional structure, and their respective precursor forms are inactive until cleaved by the intracellular cysteine protease caspase-1. Patients with mutations in the NALP3 gene, which controls the activity of caspase-1, readily secrete more IL-1beta and IL-18 and suffer from systemic inflammatory diseases. Patients with defects in this gene have high circulating concentrations of IL-6, serum amyloid A, and C-reactive protein, each of which decrease rapidly upon blockade of the IL-1 receptor, which suggests that IL-1beta contributes to the elevation of these markers of the inflammatory mechanisms of aging. Animal studies support the concept that IL-1beta and IL-18 participate in the pathogenesis of atherosclerosis. For example, overexpression of the IL-18 binding protein, a naturally occurring, specific inhibitor of IL-18, prevents the spontaneous development of atherosclerosis in apolipoprotein E-deficient mice. From human and animal studies, one may conclude that IL-1beta and IL-18 participate in fundamental inflammatory processes that increase during the aging process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470011     DOI: 10.1093/ajcn/83.2.447S

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  134 in total

1.  Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice.

Authors:  Julia Menke; Tillmann Bork; Birte Kutska; Katelyn T Byrne; Michaela Blanfeld; Manfred Relle; Vicki R Kelley; Andreas Schwarting
Journal:  Kidney Int       Date:  2010-10-27       Impact factor: 10.612

2.  Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.

Authors:  Gipsy Majumdar; Robert J Rooney; I Maria Johnson; Rajendra Raghow
Journal:  Physiol Genomics       Date:  2011-09-27       Impact factor: 3.107

Review 3.  Drivers of age-related inflammation and strategies for healthspan extension.

Authors:  Emily L Goldberg; Vishwa Deep Dixit
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

4.  Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease.

Authors:  M Reale; M A Kamal; L Velluto; D Gambi; M Di Nicola; N H Greig
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

5.  Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit.

Authors:  Xiangzhi Meng; Michael Leman; Yan Xiang
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

6.  Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency.

Authors:  Eric P Zorrilla; Manuel Sanchez-Alavez; Shuei Sugama; Molly Brennan; Rosette Fernandez; Tamas Bartfai; Bruno Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

7.  Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture.

Authors:  J V Fahey; J A Wright; L Shen; J M Smith; M Ghosh; R M Rossoll; C R Wira
Journal:  Mucosal Immunol       Date:  2008-05-14       Impact factor: 7.313

Review 8.  Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.

Authors:  S Samuel Weigt; Vyacheslav Palchevskiy; John A Belperio
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

Review 9.  Inflammasomes bridge signaling between pathogen identification and the immune response.

Authors:  A A Abdul-Sater; N Saïd-Sadier; D M Ojcius; O Yilmaz; K A Kelly
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

10.  Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

Authors:  Hanfen Li; Stephen B Willingham; Jenny P-Y Ting; Fabio Re
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.